1

2

3 4

6 7

5

8

9

10 11

12

13 14

1516

17 18

19

20

21 22

2324

26 27

25

28 29 30

<u>REMARKS</u>

Status of the Claims

Claims 2, 4-11, 14, 15, 17-41, 43, 44, 55-61, 88, 89, and 97 are pending in the present application, Claims 1, 3, 12, 13, 16, 42, 45-54, 62-73, 75, 79-87, 90-96 and 99-100 having been previously canceled, Claims 74, 76-78, and 98 having been currently canceled herein, and Claims 2, 55, and 57 having been amended to more clearly distinguish the recited subject matter over the cited art.

Brief Summary of Examiner Musselman's Telephone Message

Applicant acknowledges receipt of Examiner Musselman's voicemail message on Tuesday, May 12, 2009. Examiner Musselman indicated that he had reviewed the proposed amendments that had been informally faxed to him earlier and it appeared that the proposed amendments overcame the prior art. Examiner Musselman also suggested that the proposed amendments be submitted formally. Examiner Musselman indicated that he would call applicant's attorney if additional cited art became available so that a discussion could take place at that point.

Applicant very much appreciates Examiner Musselman's willingness to review the proposed amendments, as applicant's intention is to place all of the claims in a condition for allowance with this amendment.

Allowable Subject Matter

Claims 88, 89, and 97 are allowed.

Claims Rejected under 35 U.S.C. § 102(b)

Claims 2, 7, 9, 11, 14, 15, 17, 20-28, 31, 34-37, 43, 44 and 55-61 have been rejected under 35 U.S.C. § 102(b) as being anticipated by U.S. Patent No. 4,134,218 (Adams et al.-hereinafter referred to as "Adams").

Applicant respectfully disagrees with the above rejections for at least the following reasons.

In the interest of reducing the complexity of the issues for the Examiner to consider in this response, the following discussion focuses on independent Claims 2, 55, and 57.

The patentability of each remaining dependent claim is not necessarily separately addressed in detail. However, applicant's decision not to discuss the differences between the cited art and each dependent claim should not be considered as an admission that applicant concurs with the Examiner's conclusion that these dependent claims are not patentable over the disclosure in the cited references.

Similarly, applicant's decision not to discuss differences between the prior art and every claim element, or every comment made by the Examiner, should not be considered as an admission that applicant concurs with the Examiner's interpretation and assertions regarding those claims. Indeed, applicant believes that all of the dependent claims patentably distinguish over the references cited. In any event, a specific traverse of the rejection of each dependent claim is not required, since dependent claims are patentable for at least the same reasons as the independent claims from which the dependent claims ultimately depend.

Patentability of Independent Claims 2, 55 and 57 over Adams

Applicant has amended independent Claims 2, 55 and 57 to clarify that the *evaluation circuit* is self healing in order to further distinguish these claims over the Adams reference. Applicant believes there is support in the specification for such an amendment, as found on page 61, lines 20-23 wherein it is disclosed that despite repeated punctures with a needle, that no damage is done to the conductive elastomer, such as causing a short in the circuit.

Accordingly, the rejection of independent Claims 2, 55 and 57 under 35 U.S.C. § 102(b) should be withdrawn.

Since dependent claims inherently include all of the recitation of the independent claims from which they ultimately depend, for at least the same reasons as noted above in connection with independent Claims 2, 55 and 57, the rejection of their dependent claims should also be withdrawn.

Claims Rejected under 35 U.S.C.§ 103(a)

Claims 4-6, 74, 76, 77, and 98 have been rejected under 35 U.S.C. § 103(a) as being unpatentable over Adams in view of U.S. Patent No. 5,175,214 (Takaya et al.-hereinafter referred to as "Takaya").

Claims 8, 10 and 18-19 have been rejected under 35 U.S.C. § 103(a) as being unpatentable over Adams.

Claims 29, 30, 32, 33, and 78 have been rejected under 35 U.S.C.§ 103(a) as being unpatentable over Adams in view of U.S. Patent No.5,853,292 (Eggert et al.-hereinafter referred to as "Eggert").

Claims 38-41 have been rejected under 35 U.S.C.§ 103(a) as being unpatentable over Adams in view of U.S. Patent No. 4,872,841 (Hamilton et al.-hereinafter referred to as "Hamilton").

5

8

10 11

13 14

12

1516

171819

20 21

2223

24

252627

28 29

30

Patentability of Independent Claim 74

Independent Claim 74 has been canceled, so its rejection is now moot.

The rejection of dependent Claims 76 and 77 is also moot, as these claims have also been canceled.

Patentability of Independent Claim 98

Independent Claim 98 has been canceled, so its rejection is now moot.

Patentability of Dependent Claims 4-6

Dependent claims inherently include all of the recitation of the independent claims from which they ultimately depend. Thus, for at least the same reasons as noted above in connection with independent Claim 2 and because the additional cited art of Takaya does not cure the deficiencies outlined above, the rejection of dependent Claims 4-6 should be withdrawn.

Patentability of Dependent Claims 8, 10 and 18-19

Dependent claims inherently include all of the recitation of the independent claims from which they ultimately depend. Thus, for at least the same reasons as noted above in connection with independent Claim 2, dependent Claims 8, 10 and 18-19 should be withdrawn.

Patentability of Dependent Claims 29, 30, 32, and 33

Dependent claims inherently include all of the recitation of the independent claims from which they ultimately depend. Thus, for at least the same reasons as noted above in connection with independent Claim 2 and because the additional cited art of Eggert does not cure the deficiencies outlined above, the rejection of dependent Claims 29, 30, 32, and 33 should be withdrawn.

Patentability of Dependent Claim 78

Dependent Claim 78 has been canceled, so its rejection is now moot.

Patentability of Dependent Claims 38-41

Dependent claims inherently include all of the recitation of the independent claims from which they ultimately depend. Thus, for at least the same reasons as noted above in connection with independent Claim 2 and because the additional cited art of Hamilton does not cure the deficiencies outlined above, the rejection of dependent Claims 38-41 should be withdrawn.

Conclusion

In consideration of the amendment to the claims and the Remarks set forth above, it is applicant's position that all claims in the current application are patentable over the art of record.

1	The Examiner is thus requested to pass this case to issue without further delay. In the event that any
2	other issues remain, the Examiner is invited to telephone applicant's attorney at the number listed
3	below.
4	
5	
6	Respectfully submitted,
7	
8	/cobring to magintura/
9	/sabrina k. macintyre/ Sabrina K. MacIntyre
10	Registration No. 56,912
11	SKM/RMA:elm
12	
13	
14	
15	
16	
17	
18	
19	
20 21	
22	
23	
24	
25	
26	
27	
28	
29	
20	

-15-